Methodological advances in drug discovery for Chagas disease

Area of Science:

• Tropical infectious diseases
• Drug discovery and development
• Parasitology

Background:

• Chagas disease is a major public health concern in Latin America, causing significant myocarditis globally.
• Existing treatments for Chagas disease have limitations including variable efficacy, side effects, and difficulty in confirming effectiveness.
• Current in vitro and in vivo drug efficacy assessment systems hinder the development of more effective anti-Trypanosoma cruzi compounds.

Purpose of the Study:

• To review the evolution of Chagas disease drug discovery methodologies.
• To highlight recent advancements in high-throughput screening, in vivo testing, and human efficacy assessments.
• To discuss the potential for new Chagas disease treatments based on improved screening tools.

Main Methods:

• Review of recent literature on Chagas disease drug discovery.
• Focus on developments in high-throughput screening (HTS) for anti-T. cruzi compounds.
• Analysis of progress in in vivo testing models and human clinical trial methodologies.

Main Results:

• Significant progress in the last 5 years has improved both target-focused and HTS for compound libraries against T. cruzi.
• Development of advanced in vitro and in vivo screening tools has dramatically improved.
• Availability of effective in vivo testing models alleviates bottlenecks in demonstrating compound efficacy in relevant animal systems.

Conclusions:

• Recent improvements in screening technologies show great potential for developing novel Chagas disease treatments.
• Enhanced methodologies facilitate faster and more definitive assessment of anti-T. cruzi compound efficacy.
• Increased coordination of research and development efforts, along with funding, is crucial for translating these advances into new therapies.